Neuropathic Pain Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The neuropathic pain market size has grown strongly in recent years. It will grow from $5.35 billion in 2024 to $5.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing demand for neuropathic pain drugs, chronic pain epidemic, growing demand for prescription treatments, government initiatives.

The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $7.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to growing awareness of neuropathic pain, aging population, well-proliferated healthcare sector, accessibility to neuropathic pain treatments. Major trends in the forecast period include improved diagnostics, advancements in pain management, advancements in medical research, new drug approvals, strategic initiatives.

The increasing prevalence of chronic pain is expected to drive the growth of the neuropathic pain market. Chronic pain is ongoing and persistent pain that continues beyond the typical healing period for an injury or illness, lasting at least three to six months or more. The rising incidence of chronic pain, including neuropathic conditions, highlights the need for effective treatments, driving research, innovation, and investment in new therapies aimed at improving symptom relief and quality of life. For example, in December 2023, the Scottish Health Survey 2022, published by the Scottish Government, revealed that over one-third (38%) of adults in Scotland reported experiencing pain or discomfort lasting three months or longer, with a higher prevalence in women (43%) compared to men (33%). As a result, the increasing prevalence of chronic pain is fueling the growth of the neuropathic pain market.

The anticipated rise in diabetes cases is expected to drive the growth of the neuropathic pain market. Diabetes is a chronic condition characterized by high blood glucose levels. One of its most common complications is diabetic neuropathy, with more than 50% of diabetic patients experiencing some form of neuropathy during their lifetime. Diabetic peripheral neuropathy (DPN) is the most common type of neuropathy and is associated with established treatment methods. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported a significant rise in diabetes cases among individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. This sharp rise highlights the growing prevalence of diabetes, especially among younger populations. As a result, the increasing number of diabetes cases is driving the growth of the neuropathic pain market.

The leading companies in the neuropathic pain market are embracing artificial intelligence technologies to revolutionize various facets of pain management. These innovations encompass advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery, and data-driven insights, all aimed at optimizing patient outcomes and refining pain management strategies. For instance, in March 2023, Nevro Corp., a U.S.-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This cutting-edge technology harnesses the power of artificial intelligence (AI) to deliver customized pain relief solutions for individual patients. The system, which comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. Utilizing a unique algorithm informed by extensive patient data, the system allows patients to fine-tune their pain relief programs through a smartphone app. The digital ecosystem of the system enables continuous data collection and potential updates. The primary goal of this technology is to elevate pain relief by offering consistency and personalization, representing a significant advancement in SCS therapy.

In July 2023, Novartis AG, a Switzerland-based multinational pharmaceutical company specializing in innovative medicines, acquired DTx Pharma for an undisclosed amount. This acquisition enables Novartis to leverage DTx's expertise in small interfering ribonucleic acid (siRNA) therapies for neurological disorders, strengthening its ability to address unmet medical needs and accelerate the development of new treatments for patients. DTx Pharma, a US-based preclinical biotechnology company, focuses on developing RNA-based therapies for neuropathic pain.

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.

North America was the largest region in the neuropathic pain market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuropathic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuropathic pain market consists of revenues earned by entities by providing physical therapy services, acupuncture services and relaxation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuropathic pain market also includes sales of anticonvulsants, antidepressants, opioids, topical creams and transcutaneous electrical nerve stimulation devices, which are used in providing neuropathic pain diagnosis and treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Neuropathic pain, a persistent condition resulting from nervous system damage or dysfunction, is characterized by sensations like burning, tingling, shooting, or electric shocks. Treating neuropathic pain can be complex, with causes including nerve injuries, diabetes, multiple sclerosis, nerve compression, neural degeneration, and central nervous system disorders.

The primary approaches to neuropathic pain treatment include medications and multimodal therapy. Medications involve the use of pharmaceutical substances to alleviate symptoms and manage conditions. Certain drugs, such as anticonvulsants, antidepressants, and opioids, are effective in targeting nerve-related abnormalities and pathways. They work to reduce the intensity of neuropathic pain signals, offering relief. Neuropathic pain diagnosis typically involves imaging, blood tests, and physical examinations. These diagnostic procedures are relevant for conditions like diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. They are commonly administered in healthcare settings such as hospitals, clinics, home healthcare, and ambulatory surgical centers.

The neuropathic pain market research report is one of a series of new reports that provides neuropathic pain market statistics, including neuropathic pain industry global market size, regional shares, competitors with a neuropathic pain market share, detailed neuropathic pain market segments, market trends and opportunities and any further data you may need to thrive in the neuropathic pain industry. This neuropathic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.